Disperse Red 9, also known as C.I. Solvent Red 24, is an azo dye widely used in textile dyeing, particularly for polyester fabrics. It is characterized by its brilliant red color and good fastness properties. The synthesis of Disperse Red 9 typically involves diazotization of 4-aminoazobenzene followed by coupling with 2-hydroxy-3-naphthoic acid. Research into Disperse Red 9 often focuses on its environmental impact, including its potential for bioaccumulation and toxicity. Furthermore, studies explore alternative synthesis methods that are more sustainable and environmentally friendly. The importance of studying Disperse Red 9 lies in its widespread use and the need to ensure its safe and responsible production and application.'
| ID Source | ID |
|---|---|
| PubMed CID | 6706 |
| CHEMBL ID | 1370390 |
| SCHEMBL ID | 1050030 |
| MeSH ID | M0126665 |
| Synonym |
|---|
| BIDD:GT0779 |
| alpha-methylaminoanthraquinone |
| macrolex red gs |
| einecs 201-417-2 |
| solvent red 111 |
| nsc 3721 |
| 1-(methylamino)-9,10-anthracenedione |
| brn 1973186 |
| ai3-18871 |
| oracet red g |
| 9,10-anthracenedione, 1-(methylamino)- |
| amaplast red aap |
| kayaset red g |
| smoke red m |
| 1-(methylamino)anthra-9,10-quinone |
| nsc3721 |
| anthraquinone, 1-(methylamino)- |
| celanthrene red y |
| supracet pink r |
| 82-38-2 |
| nsc-3721 |
| macrolex red g |
| duranol red gn |
| 1-(n-methylamino)-9,10-anthraquinone |
| c.i. disperse red 9 |
| 9, 1-(methylamino)- |
| waxoline red maa |
| n-methyl-1-anthraquinonylamine |
| 1-(methylamino)-9,10-anthraquinone |
| 1-(methylamino)anthraquinone |
| 1-(n-methylamino)anthraquinone |
| c.i. 60505 |
| c.i. solvent red 111 |
| diacelliton fast pink r |
| celliton pink r |
| macro-lex red g |
| disperse red 9 |
| methane quinone |
| waxoline red mp |
| serilene fast pink bt |
| .alpha.-methylaminoanthraquinone |
| MLS000402447 , |
| smr000263676 |
| 1-(methylamino)anthracene-9,10-dione |
| inchi=1/c15h11no2/c1-16-12-8-4-7-11-13(12)15(18)10-6-3-2-5-9(10)14(11)17/h2-8,16h,1h |
| 1-(methylamino)anthraquinone, 98% |
| STK238274 |
| AC-11724 |
| 1-methylaminoanthraquinone |
| M0255 |
| AKOS000120989 |
| A840316 |
| NCGC00246029-01 |
| HMS2516K17 |
| unii-5o1807mll1 |
| 5o1807mll1 , |
| solvaperm red pfs |
| FT-0625339 |
| SCHEMBL1050030 |
| 1-(methylamino)-9,10-dihydroanthracene-9,10-dione |
| DTXSID2052570 |
| 1-methylaminoanthrachinon |
| AE-641/00206002 |
| W-104178 |
| bdbm51054 |
| cid_6706 |
| anthraquinone, 1-methylamine |
| 1-(methylamino)anthra-9,10-quinone # |
| CHEMBL1370390 |
| mfcd00001197 |
| waxoline red mp-fw |
| diaresin red s |
| sandoplast red pfs |
| transparent red gs |
| solvaperm red 111 |
| oplas red 330 |
| kp plast red g |
| CCG-242557 |
| Z56821896 |
| EN300-16914 |
| STR04992 |
| D95310 |
| CS-0010137 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In the same species several other adverse findings were noted: these included adenocarcinomas of the breast in the high-dose group and a dose-related incidence of biliary hyperplasia." | ( Inhalation toxicity of a smoke containing Solvent Yellow 33, Disperse Red 9 and Solvent Green 3 in laboratory animals. Brown, RF; Colgrave, HF; Gazzard, M; Marrs, TC, 1984) | 0.51 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 8.9125 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 2.8184 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 9.5283 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| BRCA1 | Homo sapiens (human) | Potency | 11.2202 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 18.7556 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
| TDP1 protein | Homo sapiens (human) | Potency | 29.0929 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 8.9125 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 3.9811 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| 67.9K protein | Vaccinia virus | Potency | 11.2202 | 0.0001 | 8.4406 | 100.0000 | AID720580 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 3.1623 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| P53 | Homo sapiens (human) | Potency | 5.6234 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 8.9125 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 8.9125 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 12.7503 | 0.0398 | 16.7842 | 39.8107 | AID1454; AID1724; AID1725 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 6.3096 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
| epidermal growth factor receptor isoform a precursor | Homo sapiens (human) | Potency | 19.9526 | 0.0008 | 0.4819 | 3.5481 | AID1729 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 1.6947 | 1.1998 | 14.6419 | 50.1187 | AID720540 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 75.6863 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 8.9125 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 35.4813 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 10.0000 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 28.1838 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| C-terminal-binding protein 1 | Homo sapiens (human) | Potency | 2.3938 | 0.3014 | 9.3210 | 19.0148 | AID720541 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| nonstructural protein 1 | Influenza A virus (A/California/07/2009(H1N1)) | IC50 (µMol) | 8.1800 | 0.2000 | 24.4540 | 100.0000 | AID504329 |
| polyadenylate-binding protein 1 | Homo sapiens (human) | IC50 (µMol) | 57.5750 | 4.9100 | 23.7029 | 76.1900 | AID602259; AID602260 |
| Protein skinhead-1 | Caenorhabditis elegans | IC50 (µMol) | 100.0000 | 7.3900 | 21.5238 | 43.9000 | AID624474 |
| BZLF2 | Human herpesvirus 4 type 2 (Epstein-Barr virus type 2) | IC50 (µMol) | 2.8000 | 0.4200 | 4.4342 | 16.2300 | AID1419 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| nucleus | C-terminal-binding protein 1 | Homo sapiens (human) |
| nucleoplasm | C-terminal-binding protein 1 | Homo sapiens (human) |
| presynaptic active zone cytoplasmic component | C-terminal-binding protein 1 | Homo sapiens (human) |
| glutamatergic synapse | C-terminal-binding protein 1 | Homo sapiens (human) |
| GABA-ergic synapse | C-terminal-binding protein 1 | Homo sapiens (human) |
| transcription repressor complex | C-terminal-binding protein 1 | Homo sapiens (human) |
| nucleus | C-terminal-binding protein 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.66) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||